Lactate Dehydrogenase-to-Albumin Ratio Predicts 30-Day and 90-Day Mortality in Glucocorticoid-Treated ICU Patients With Pneumonia: A Secondary Analysis of a Multicenter Cohort - Report - MDSpire

Lactate Dehydrogenase-to-Albumin Ratio Predicts 30-Day and 90-Day Mortality in Glucocorticoid-Treated ICU Patients With Pneumonia: A Secondary Analysis of a Multicenter Cohort

  • By

  • Han, Dan dan

  • Sun, fa Sheng

  • Liu, Ai

  • Hao, Cuiping

  • Sun, ping Jian

  • April 16, 2026

  • 0 min

Share

Clinical Report: Lactate Dehydrogenase to Albumin Ratio as a Predictor of Mortality

Overview

The lactate dehydrogenase-to-albumin ratio (LAR) is a significant predictor of 30-day and 90-day mortality in ICU patients with pneumonia undergoing glucocorticoid treatment. An optimal LAR cutoff of 13.39 was identified, with high LAR correlating with increased mortality rates.

Background

Accurate risk stratification in pneumonia patients receiving glucocorticoids is challenging due to the confounding effects of these medications on traditional inflammatory biomarkers. The LAR serves as a potential tool for assessing cellular injury and nutritional status, which may enhance prognostic capabilities in this population. Understanding mortality predictors is crucial for improving patient outcomes in critical care settings.

Data Highlights

Mortality RateHigh LAR (≥13.39)Low LAR (<13.39)
30-day45.8%12.1%
90-day51.4%14.3%

Key Findings

  • The optimal LAR cutoff for predicting 30-day mortality was determined to be 13.39.
  • High LAR was associated with significantly higher 30-day and 90-day mortality rates (both P < 0.001).
  • High LAR remained an independent predictor of mortality after multivariable adjustment (HR 2.07 for 30-day, HR 1.93 for 90-day).
  • LAR demonstrated good discrimination with an AUC of approximately 0.74.
  • Incorporating LAR into clinical assessments may enhance early risk stratification.

Clinical Implications

The LAR is a simple and readily available biomarker that can aid in identifying high-risk pneumonia patients receiving glucocorticoids. Clinicians should consider integrating LAR into routine assessments to improve individualized management and potentially enhance patient outcomes.

Conclusion

LAR is a valuable prognostic tool for predicting short- and mid-term mortality in ICU pneumonia patients on glucocorticoids. Its incorporation into clinical practice may facilitate better risk stratification and management strategies.

References

  1. Frontiers in Medicine, 2026 -- Clinical utility of the lactate-to-albumin ratio for predicting mortality in elderly severe acute pancreatitis
  2. conexiant -- Lactate–Albumin Ratio Tied to TBI Mortality
  3. Intensive Care Medicine -- Prioritize Lactate Measurement Over Vital Signs in Sepsis Assessment
  4. Open Forum Infectious Diseases -- Evaluation of Lateral Flow Assays for Aspergillus Antigen Detection in Critically Ill Patients with Invasive Pulmonary Aspergillosis: A Multicenter ICU Study
  5. (PDF) Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline
  6. Effectiveness of Hydrocortisone in Severe Community-acquired Pneumonia: A Meta-analysis of Mortality, Mechanical Ventilation Needs, and Inflammatory Outcomes | American Journal of Respiratory and Critical Care Medicine
  7. (PDF) Diagnosis and Management of Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline
  8. Effectiveness of Hydrocortisone in Severe Community-acquired Pneumonia: A Meta-analysis of Mortality, Mechanical Ventilation Needs, and Inflammatory Outcomes | American Journal of Respiratory and Critical Care Medicine

Original Source(s)

Related Content